| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Common Stock | Award | $0 | +56.7K | +1.04% | $0.00 | 5.49M | Feb 14, 2024 | Direct | F3 |
| transaction | MRNA | Common Stock | Sale | -$2.34M | -26.4K | -0.48% | $88.88 | 5.46M | Feb 16, 2024 | Direct | F4 |
| holding | MRNA | Common Stock | 9.05M | Feb 14, 2024 | See Footnote | F1 | |||||
| holding | MRNA | Common Stock | 6.56M | Feb 14, 2024 | See Footnote | F2 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F2 | These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F3 | The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 5, 2021 (the "2021 PSUs"). |
| F4 | Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the 2021 PSUs. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person. |